Chimerix (NASDAQ:CMRX) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.11, Fidelity Earnings reports. The firm had revenue of $1.85 million during the quarter, compared to analyst estimates of $1.50 million. Chimerix had a negative net margin of 899.68% and a negative return on equity of 33.56%.
CMRX stock traded up $0.04 during midday trading on Friday, reaching $1.77. The company’s stock had a trading volume of 543,148 shares, compared to its average volume of 414,301. The stock has a fifty day simple moving average of $1.83 and a two-hundred day simple moving average of $1.99. Chimerix has a 1 year low of $1.25 and a 1 year high of $4.40. The firm has a market capitalization of $114.84 million, a price-to-earnings ratio of -0.88 and a beta of 1.55.
In other Chimerix news, insider Garrett Nichols sold 30,680 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $2.15, for a total value of $65,962.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 42,035 shares of company stock worth $85,089. Insiders own 9.40% of the company’s stock.
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Featured Article: How to build a Fibonacci channel
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.